Pliant Therapeutics vs Arcus Biosciences
PLRX and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLRX and RCUS compare
Arcus Biosciences is the larger company, worth 49 times as much as Pliant Therapeutics ($2.3B against $45.8M).
Pliant Therapeutics scores higher on the StockData Score (6 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLRX | RCUS |
|---|---|---|
| Size and price | ||
| Market cap | $45.8M | $2.3B |
| Share price | $0.740 | $17.77 |
| Change, 1 year | −55.7% | −12.4% |
| Change, 5 years | −95.1% | −62.6% |
| Beta (5Y) | 1.00 | 1.41 |
| Employees | 49 | 601 |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 22.6× |
| P/B | 0.4× (better) | 6.3× |
| FCF yield | −146% | −20.6% (better) |
| Fair value | – | $5.88 |
| Margin of safety | – | −202% |
| Growth | ||
| Revenue growth (TTM) | – | −58.3% |
| Revenue growth, 5Y average | – | 25.9% |
| Profitability | ||
| Operating margin | – | −475% |
| Net margin | – | −453% |
| FCF margin | – | −466% |
| Return on equity | −55.3% (better) | −114% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −698.2× | −43.2× (better) |
| Current ratio | 8.05 (better) | 3.34 |
| Altman Z-score | −7.95 | −1.30 (better) |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | −12.3% |
| Shareholder yield | 0.00% (better) | −12.3% |
| Ownership | ||
| Held by institutions | 77.7% | 96.3% |
| Held by insiders | 13.0% | 31.7% |
| Insider net buying, 12 months | −$164K (better) | −$9.3M |
| Short interest, % of float | 9.1% | 15.2% |
Go deeper
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.